Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1549-1552

  Lindbäck, Stefan ^a,b   Vizzard, Jeanette ^a,b   Cooper, David A ^a,b   Gaines, Hans ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEXUAL BEHAVIOR; ZIDOVUDINE;

EID: 0032995701     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314777     Document Type: Article

References (15)

1. 1. Feinberg MB, Carpenter C, Fauci AS, et al. Report of the NHI panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998;128:1057-100.
2. 2. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175: 1051-5.
3. 3. Gaines H, Lindbäck S, Sönnerborg A, Karlsson A. Plasma HIV-RNA levels in 20 patients with or without treatment during primary HIV-1 infection [abstract 108]. Presented at the Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, 1997.
4. 4. Hoen B, Harzic M, Fleury HF, et al. ANRS053 trial of zidovudine (ZDV), lamivudine (3TC), and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandrin, VA: Infectious Diseases Society of America, 1997:232.
5. 5. Tindall B, Gaines H, Imrie A, et al. Zidovudine in the management of primary HIV-1 infection. AIDS 1991;5:477-84.
6. 6. Niu MT, Jermano JA, Reichelderfer P, Schnittman SM. Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1993;9: 913-24.
7. 7. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
8. 8. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 1998;175:80-91.
9. 0/L, AIDS, and death from AIDS? BMJ 1994;309: 1535-7.
10. 10. Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990;301:1183-8.
11. 11. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154-7.
12. 12. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351: 543-9.
13. 13. No authors listed. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
14. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
15. + T-cell phenotype and depletions within the CD4 T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-40.